DeepCure Showcases Powerful New Treatment for RA That Outshines Etanercept

DeepCure's Groundbreaking Presentation on DC-9476

Recently, DeepCure, a pioneering therapeutics company leveraging artificial intelligence to develop innovative drugs for immune and inflammatory diseases, announced significant findings regarding its selective BRD4 (BD2) inhibitor, DC-9476. The data reveals that DC-9476 performs better than the conventional anti-TNF-? treatment known as etanercept in mouse models of rheumatoid arthritis (RA).

Understanding Rheumatoid Arthritis

Rheumatoid arthritis is a chronic autoimmune disorder characterized by a particularly aggressive inflammation of the joints. One of the key players in the progression of this condition is activated macrophages, which generate inflammatory cytokines such as TNF-?, IL-1?, and IL-6, leading to joint destruction and considerable pain for those affected.

The Power of DC-9476

DC-9476 has undergone rigorous evaluation through various preclinical studies aiming to establish its efficacy as a potential treatment for RA. The in vitro assessments showed that when human macrophages were stimulated, DC-9476 effectively reduced IL-6 production, proving to be more potent than tofacitinib, a known Jak-2 inhibitor currently in use for RA cases.

In Vivo Findings of Efficacy

The impressive efficacy of DC-9476 was further demonstrated in two different mouse models. First, in an inflammatory model triggered by lipopolysaccharide (LPS), DC-9476 significantly decreased the levels of serum IL-6 and TNF-?. In the collagen antibody-induced arthritis model, which closely mirrors macrophage-driven RA, DC-9476 led to over an 80% reduction in clinical disease scores. This was substantially better than etanercept, which achieved only a 47% reduction in the same context. Notably, throughout these studies, DC-9476 exhibited no observable toxicity.

Combination Therapy Benefits

Moreover, it was discovered that when DC-9476 was combined with etanercept, there were substantial enhancements in therapeutic outcomes compared to each treatment being administered alone. This indicates that DC-9476 could serve as not only a standalone treatment but also as a powerful adjunct in combination therapies for RA patients.

Details of an Important Presentation

DeepCure will present these exciting findings in a poster titled: "Novel, Selective BRD4 (BD2) Inhibitor DC-9476 Demonstrates a Potent Anti-inflammatory Mechanism." This presentation is slated for October 19 at 10:25 am local time, with Dr. Michal Segal-Salto, Senior Director of Biology at DeepCure, as the presenter.

Kfir Schreiber, CEO & Co-Founder of DeepCure, commented on this significant moment: "This is the first time we are presenting in vivo data in animal models of RA for DC-9476, which demonstrates its potential as a novel oral monotherapy or combination therapy for patients. In addition, this selective BRD4 (BD2) inhibitor reduced key inflammatory cytokines that could be used as biomarkers of target engagement in future clinical trials."

About DeepCure and Its Vision

DeepCure is dedicated to advancing novel therapeutic solutions for inflammation and autoimmune diseases. Founded by a group of MIT researchers, the company harnesses the power of artificial intelligence along with cutting-edge technologies in small molecule discovery. Based in Boston, the collaborative efforts of its engineers, chemists, and biologists focus on addressing complex issues that can lead to transformative impacts on patient health and outcomes.

Frequently Asked Questions

What is DC-9476?

DC-9476 is a selective BRD4 (BD2) inhibitor developed by DeepCure aimed at treating rheumatoid arthritis.

How does DC-9476 compare to standard treatments?

In preclinical studies, DC-9476 has shown superior efficacy compared to etanercept, the current anti-TNF-? treatment.

What are the benefits of combination therapy with DC-9476?

Combining DC-9476 with etanercept yielded significantly better results than using either treatment alone.

When and where will the presentation take place?

The presentation will occur on October 19 at 10:25 am local time, highlighting the promising findings of DC-9476.

What is DeepCure's mission?

DeepCure aims to discover and develop novel drugs using AI to transform the treatment landscape for autoimmune and inflammatory diseases.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.